DNA methylation signature predictive of benefit from neoadjuvant chemotherapy in esophageal adenocarcinoma: Results from the MRC OEO2 phase III trial.
Sundar R, Ng A, Zouridis H, Sheng T, Zhang S, Lee M, Padmanabhan N, Ooi W, Qamra A, Nankivell M, Langley R, Allum W, Cunningham D, Grabsch H, Tan P. DNA methylation signature predictive of benefit from neoadjuvant chemotherapy in esophageal adenocarcinoma: Results from the MRC OEO2 phase III trial. Journal Of Clinical Oncology 2019, 37: 43-43. DOI: 10.1200/jco.2019.37.4_suppl.43.Peer-Reviewed Original ResearchDNA methylationCpG sitesMethylation signaturesChemotherapy benefitNeoadjuvant chemotherapyPoor riskGood riskMethylation statusDNA methylation of genesIndependent predictor of survivalDNA methylation signaturesPredictive marker of survivalIllumina GoldenGate platformMethylation of genesCycles of cisplatinCox proportional hazards analysisResectable esophageal carcinomaMarker of survivalPredictive of benefitPredictors of survivalProportional hazards analysisGoldenGate platformSite signatureEpigenetic signaturesSurgery arm